Predictive supply planning, working IRT study protocols in 72 hours, and integration across the clinical supply chain support industry demand for greater speed, accuracy and agility
Predictive supply planning, working IRT study protocols in 72 hours, and integration across the clinical supply chain support industry demand for greater speed, accuracy and agility
Doylestown, PA - Bioclinica eHealth Solutions division, which provides an agile ecosystem and domain expertise for sponsors and CROs to speed clinical development, has released the industry’s only purpose-built, end-to-end, configurable randomization and trial supply management (RTSM) software platform. Bioclinica AGILE RTSM provides seamless clinical supply forecasting and management together with IRT to meet the industry’s demand for greater end-to-end efficiencies in the face of increasing time, cost and resource constraints. The flexible, intelligent RTSM platform combines the latest release of Bioclinica’s Trident Agile IRT and the advanced Optimizer clinical supply forecasting and management software to significantly cut time, effort and cost for even the most complex global trials.
“Traditional, siloed and heavily customized systems create significant efficiency gaps, with costly re-work and drawn-out timelines,” said Bioclinica eHealth Solutions President Mukhtar Ahmed. “Our customers are able to view working IRT studies from their protocols in as little as 72 hours, and implement, test and deploy within 7-10 days. Because the RTSM system also integrates with clinical, manufacturing and ERP systems, customers are reducing drug waste and study costs by millions of dollars, and identifying changing trial conditions months in advance to reduce patient and study risk.”
The Bioclinica AGILE RTSM platform provides real-time visibility and reforecasting capability based on study actuals. By combining Bioclinica Optimizer supply management functionality with Trident Agile IRT, clinical operations personnel and clinical supply managers can easily create and compare supply plans, accurately predict demand months in advance, and manage supplies with the ability to analyze study requirements in real time − helping detect and prevent potential supply issues.
Bioclinica’s global expert services teams are skilled in implementing the Agile RTSM methodology, which involves adaptive planning, evolving development and the use of functional software, rather than the development of specification documents prior to the study build. Study managers can evaluate working software and provide immediate feedback − resulting in a faster sign-off and approval process, as well as a study that precisely matches the protocol and study objectives.
Integration across the clinical supply chain and development process enables Bioclinica’s customers to:
“With this latest release of Trident Agile IRT and its integration with Optimizer, Bioclinica offers a one-of-a-kind AGILE RTSM platform to deliver far greater efficiency, together with expert services to support any customer and any trial, anywhere in the world,” noted Ahmed.
About Bioclinica
Bioclinica is a specialty services provider that utilizes expertise and technology to create clarity in the clinical trial process. Bioclinica is organized by three business segments to deliver focused service supporting multifaceted technologies. The Medical Imaging & Biomarkers segment provides medical imaging and cardiac safety services and includes a molecular marker laboratory. The eHealth Solutions segment comprises the eClinical Solutions platform; Financial Lifecycle Solutions; Safety & Regulatory Solutions; Strategic Consulting Services; App xChange Alliances; and eHealth Cloud Services. Under the Global Clinical Research segment, Bioclinica offers a network of research sites, patient recruitment services, and a post-approval research division. The Company serves more than 400 pharmaceutical, biotechnology and device organizations – including all of the top 20 – through a network of offices in the U.S., Europe and Asia.
Learn more about the AGILE RTSM Platform online, in the Bioclinica blog and on Bioclinica LinkedIn and Twitter channels. Watch the Agile IRT video.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.